Welcome to our dedicated page for Vigil Neuroscience SEC filings (Ticker: VIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vigil Neuroscience, Inc. (VIGL) SEC filings archive provides access to the company’s historical regulatory documents from its time as an independent public issuer through its acquisition by Sanofi. As a clinical-stage biotechnology company focused on microglia and TREM2-targeted therapies for neurodegenerative diseases, Vigil used its SEC reports to describe its pipeline, risk factors, and corporate developments.
Key filings include Form 8-K current reports detailing material events. One Form 8-K describes the completion of the merger on August 5, 2025, in which a wholly owned Sanofi subsidiary merged with and into Vigil, with Vigil surviving as a wholly owned subsidiary of Sanofi. That filing explains the merger consideration for common shareholders, treatment of equity awards, the resulting change in control, and the steps taken to delist and deregister Vigil’s common stock.
For trading status and listing history, investors can review the Form 25 (25-NSE) filed by The Nasdaq Stock Market LLC, which formally removed Vigil’s common stock from listing and registration under Section 12(b) of the Exchange Act. Subsequently, Vigil filed a Form 15 (15-12G) to terminate registration of its common stock under Section 12(g) and suspend its reporting obligations under Sections 13 and 15(d), noting an approximate single holder of record at the time of certification.
Earlier periodic reports and registration statements (not reproduced here) historically contained detailed disclosures on Vigil’s TREM2 agonist programs, including iluzanebart for ALSP and VG-3927 for Alzheimer’s disease, as well as financial statements and risk discussions typical for a clinical-stage biotechnology company. On this page, AI-powered tools can help summarize complex filings, highlight key sections related to the Sanofi transaction, and clarify the implications of delisting, deregistration, and contingent value rights for former VIGL shareholders.